

Andrew Mark Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8423051/publications.pdf>

Version: 2024-02-01

42
papers

1,917
citations

236925

25
h-index

289244

40
g-index

45
all docs

45
docs citations

45
times ranked

1925
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiviral and antitumor agents from a New Zealand sponge, Mycale sp. 2. Structures and solution conformations of mycalamides A and B. <i>Journal of Organic Chemistry</i> , 1990, 55, 223-227.	3.2	150
2	Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[d]-pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1823-1835.	6.4	133
3	Tyrosine kinase inhibitors. 7. 7-amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 3780-3788.	6.4	131
4	Synthesis and Structure-Activity Studies of Biphenyl Analogues of the Tuberculosis Drug (6 <i>S</i>)-2-Nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5 <i>H</i> -imidazo[2,1- <i>b</i>][1,3]oxazine (PA-824). <i>Journal of Medicinal Chemistry</i> , 2010, 53, 282-294.	6.4	104
5	4-Phenylpyrrolo[3,4- <i>c</i>]carbazole-1,3(2 <i>H</i> ,6 <i>H</i>)-dione Inhibitors of the Checkpoint Kinase Wee1. Structure-Activity Relationships for Chromophore Modification and Phenyl Ring Substitution. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4896-4911.	6.4	96
6	Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6 <i>S</i>)-2-Nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5 <i>H</i> -imidazo[2,1- <i>b</i>][1,3]oxazine (PA-824). <i>Journal of Medicinal Chemistry</i> , 2009, 52, 637-645.	6.4	88
7	Synthesis and Structure-activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 855-866.	6.4	81
8	Synthesis and Structure-Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6 <i>S</i>)-2-Nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5 <i>H</i> -imidazo[2,1- <i>b</i>][1,3]oxazine (PA-824). <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8421-8439.	6.4	80
9	Tyrosine Kinase Inhibitors. 4. Structure-Activity Relationships among <i>N</i> - and 3-Substituted 2,2'-Dithiobis(1 <i>H</i> -indoles) for <i>in vitro</i> Inhibition of Receptor and Nonreceptor Protein Tyrosine Kinases. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 58-67.	6.4	70
10	Synthesis and Structure-Activity Relationships of Varied Ether Linker Analogues of the Antitubercular Drug (6 <i>S</i>)-2-Nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5 <i>H</i> -imidazo[2,1- <i>b</i>][1,3]oxazine (PA-824). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6563-6585.	6.4	66
11	Tyrosine Kinase Inhibitors. 6. Structure-Activity Relationships among <i>N</i> - and 3-Substituted 2,2'-Diselenobis(1 <i>H</i> -indoles) for Inhibition of Protein Tyrosine Kinases and Comparative <i>in Vivo</i> Studies against Selected Sulfur Congeners. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 413-426.	6.4	62
12	Tuberculosis Drug Discovery: Challenges and New Horizons. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7489-7531.	6.4	59
13	Tyrosine Kinase Inhibitors. 13. Structure-Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3- <i>d</i>]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3915-3925.	6.4	54
14	Structure-Activity Relationships for Amide-, Carbamate-, and Urea-Linked Analogues of the Tuberculosis Drug (6 <i>S</i>)-2-Nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5 <i>H</i> -imidazo[2,1- <i>b</i>][1,3]oxazine (PA-824). <i>Journal of Medicinal Chemistry</i> , 2012, 55, 312-326.	6.4	53
15	Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4- <i>d</i>]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8103-8124.	6.4	52
16	Synthesis and Structure-Activity Relationships of Soluble 7-Substituted 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridin-2-amines and Related Ureas as Dual Inhibitors of the Fibroblast Growth Factor Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinases. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4628-4653.	6.4	47
17	7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1- <i>b</i>][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4212-4233.	6.4	47
18	Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1- <i>b</i>][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2530-2550.	6.4	46

#	ARTICLE	IF	CITATIONS
19	3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and Related 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4200-4211.	6.4	44
20	Development of (6 <i>S</i>)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 <i>H</i> -imidazo[2,1- <i>b</i>][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2329-2352.	6.4	42
21	Synthesis and Structure-Activity Relationships of 7-Substituted 3-(2,6-Dichlorophenyl)-1,6-naphthyridin-2(1 <i>H</i>)-ones as Selective Inhibitors of pp60c-src. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3134-3147.	6.4	36
22	Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1275-1280.	2.8	36
23	Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1 <i>H</i> -indole-3-alkanoic acids and 2,2'-dithiobis(1 <i>H</i> -indole-3-alkanoic acids). <i>Journal of Medicinal Chemistry</i> , 1993, 36, 2459-2469.	6.4	34
24	Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6 <i>S</i>)-2-Nitro-6-[[4-(trifluoromethoxy)benzyl]oxy]-6,7-dihydro-5 <i>H</i> -imidazo[2,1- <i>b</i>][1,3]oxazine (PA-824). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3036-3059.	6.4	33
25	Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrolo[3,4- <i>c</i>]carbazole-1,3(2 <i>H</i> ,6 <i>H</i>)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 929-933.	2.2	27
26	Tyrosine kinase inhibitors. 2. Synthesis of 2,2'-dithiobis(1 <i>H</i> -indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 598-609.	6.4	26
27	Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrolo[3,4- <i>c</i>]carbazole-1,3(2 <i>H</i> ,6 <i>H</i>)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 1276-1296.	5.5	26
28	6-Nitro-2,3-dihydroimidazo[2,1- <i>b</i>][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2583-2589.	2.2	26
29	Chemistry of the mycalamides, antiviral and antitumour compounds from a marine sponge. Part 3. Acyl, alkyl and silyl derivatives. <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1992, , 1335.	0.9	23
30	Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5 <i>H</i> -imidazo[2,1- <i>b</i>][1,3]thiazine 8-oxides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 207-213.	2.2	22
31	Chemistry of the mycalamides, antiviral and antitumour compounds from a marine sponge. Part 4. Reactions of mycalamide A and alkyl derivatives with basic nucleophiles. <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1994, , 1025.	0.9	18
32	Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal. <i>European Journal of Medicinal Chemistry</i> , 2021, 209, 112914.	5.5	17
33	Chemistry of the mycalamides, antiviral and antitumour compounds from a marine sponge. Part 5. Acid-catalysed hydrolysis and acetal exchange, double bond additions and oxidation reactions. <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1995, , 1233.	0.9	16
34	Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis. <i>Organic Process Research and Development</i> , 2017, 21, 52-59.	2.7	15
35	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112849.	5.5	13
36	Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3804-3809.	2.2	12

#	ARTICLE	IF	CITATIONS
37	Facile dimerisation of 3-benzylideneindoline-2-thiones. Journal of the Chemical Society Perkin Transactions 1, 1993, , 1835.	0.9	11
38	Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility. ACS Medicinal Chemistry Letters, 2021, 12, 275-281.	2.8	9
39	Synthesis of 7-substituted 3-aryl-1,6-naphthyridin-2-amines and 7-substituted 3-aryl-1,6-naphthyridin-2(1Hâ€š)-ones via diazotization of 3-aryl-1,6-naphthyridine-2,7-diamines. Journal of the Chemical Society, Perkin Transactions 1, 2000, , 1843-1852.	1.3	7
40	Inhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis. Annual Reports in Medicinal Chemistry, 2019, 52, 97-130.	0.9	4
41	The kinetics of the reaction between trans- dichlorobis(1,2-diaminoethane)cobalt(III) perchlorate and monoamines in dimethylformamideâ€š. Spectrophotometric and spectropolarimetric measurements. Polyhedron, 1988, 7, 1159-1167.	2.2	0
42	A Study Investigating a Possible Link Between Lens Protein in the Vitreous Fluid of Eyes After Uncomplicated Cataract Surgery and Chronic Cystoid Macular Edema. Asia-Pacific Journal of Ophthalmology, 2014, 3, 194-197.	2.5	0